Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.44 - $1.22 $2.75 Million - $7.62 Million
6,249,012 Added 2375.59%
6,512,063 $4.49 Million
Q4 2023

Feb 14, 2024

SELL
$0.23 - $1.74 $323,861 - $2.45 Million
-1,408,094 Reduced 84.26%
263,051 $134,000
Q3 2023

Nov 14, 2023

BUY
$1.41 - $2.31 $758,385 - $1.24 Million
537,862 Added 47.46%
1,671,145 $2.47 Million
Q2 2023

Aug 14, 2023

SELL
$1.5 - $3.04 $1.68 Million - $3.4 Million
-1,118,435 Reduced 49.67%
1,133,283 $1.82 Million
Q1 2023

May 15, 2023

BUY
$2.8 - $5.46 $2.39 Million - $4.66 Million
853,953 Added 61.09%
2,251,718 $6.53 Million
Q4 2022

Feb 14, 2023

BUY
$2.85 - $5.18 $3.89 Million - $7.08 Million
1,366,179 Added 4325.27%
1,397,765 $4.58 Million
Q3 2022

Nov 14, 2022

BUY
$2.85 - $8.73 $8,099 - $24,810
2,842 Added 9.89%
31,586 $119,000
Q2 2022

Aug 15, 2022

SELL
$4.69 - $9.84 $497,135 - $1.04 Million
-105,999 Reduced 78.67%
28,744 $224,000
Q1 2022

May 16, 2022

BUY
$8.44 - $16.89 $557,099 - $1.11 Million
66,007 Added 96.03%
134,743 $1.25 Million
Q4 2021

Feb 14, 2022

BUY
$14.7 - $19.89 $531,757 - $719,500
36,174 Added 111.09%
68,736 $1.08 Million
Q3 2021

Nov 15, 2021

BUY
$11.99 - $17.9 $224,452 - $335,088
18,720 Added 135.24%
32,562 $583,000
Q2 2021

Aug 16, 2021

SELL
$12.89 - $16.58 $2.58 Million - $3.32 Million
-200,453 Reduced 93.54%
13,842 $215,000
Q1 2021

May 17, 2021

SELL
$14.0 - $20.72 $844,158 - $1.25 Million
-60,297 Reduced 21.96%
214,295 $3.08 Million
Q4 2020

Feb 16, 2021

SELL
$12.67 - $26.23 $2.35 Million - $4.87 Million
-185,535 Reduced 40.32%
274,592 $5.39 Million
Q3 2020

Nov 16, 2020

BUY
$11.92 - $15.87 $4.25 Million - $5.66 Million
356,762 Added 345.15%
460,127 $5.96 Million
Q2 2020

Aug 14, 2020

SELL
$7.53 - $14.93 $2.03 Million - $4.02 Million
-269,042 Reduced 72.24%
103,365 $1.51 Million
Q1 2020

May 15, 2020

BUY
$5.69 - $17.78 $662,833 - $2.07 Million
116,491 Added 45.52%
372,407 $3.17 Million
Q4 2019

Feb 14, 2020

SELL
$10.89 - $16.79 $4.22 Million - $6.5 Million
-387,431 Reduced 60.22%
255,916 $4.22 Million
Q3 2019

Nov 14, 2019

BUY
$12.03 - $19.94 $4.36 Million - $7.22 Million
362,267 Added 128.88%
643,347 $9.08 Million
Q2 2019

Aug 14, 2019

BUY
$19.05 - $41.04 $5.06 Million - $10.9 Million
265,763 Added 1735.09%
281,080 $5.65 Million
Q1 2019

May 15, 2019

BUY
$28.4 - $41.74 $273,605 - $402,123
9,634 Added 169.52%
15,317 $0
Q2 2018

Aug 10, 2018

SELL
$35.15 - $51.45 $519,938 - $761,048
-14,792 Reduced 72.24%
5,683 $0
Q1 2018

May 11, 2018

BUY
$18.0 - $48.35 $368,550 - $989,966
20,475 New
20,475 $799,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.08B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.